Pfizer, Allergan deal dead, what could be next?
The failed $160B Pfizer-Allergan deal left experts contemplating whether more mergers will be hit by new tax rules.
The failed $160B Pfizer-Allergan deal left experts contemplating whether more mergers will be hit by new tax rules.